We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Garry
Kind
garry.king@ukkidney.org
Prof
Moin
Saleem
m.saleem@bristol.ac.uk
Prof
Moin
Saleem
m.saleem@bristol.ac.uk
Glomerular diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Utilising the RaDaR (rare kidney disease registry), a cohort of all children with Steroid Resistant Nephrotic Syndrome (SRNS) including FSGS in the UK will be identified. Data will be collected from these children and analysed for clinical and/or epidemiological patterns. Blood samples will be taken for gene analysis for gene mutations known to cause FSGS in childhood. If the patients should undergo transplantation further blood (and urine if appropriate) samples will be taken immediately prior to and within one week following transplantation. Should the disease reoccur post transplantation and the patients undergo plasma exchange (routine therapy) plasma samples and further urine and blood samples will be taken. These blood, urine and plasma samples will be analysed for biomarkers of disease activity. Utilising these results it may be possible to develop a means of predicting disease reactivation post transplantation.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Secondary causes on Nephrotic Syndrome e.g. primary diagnosis of Glomerulonephritis (IgA Nephropathy, Membranoproliferative Glomerulonephritis, Membranous Nephropathy), Vasculitis, Systemic Lupus Erythematosus, Diabetes, Obesity, Hypertension. We will exclude any patients for whom it is felt by the consenting clinician that fully informed consent is not possible.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Moin
Saleem
m.saleem@bristol.ac.uk
Garry
Kind
garry.king@ukkidney.org
Prof
Moin
Saleem
m.saleem@bristol.ac.uk
The study is sponsored by University of Bristol and funded by Medical Research Council (MRC); NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH; NephCure Kidney International (USA); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 7945
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
